^
Association details:
Biomarker:IDH2 mutation
Cancer:Glioma
Drug:Partruvix (pamiparib) (PARP inhibitor)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: C2 – Inclusion Criteria
Title:

BGB-290 and Temozolomide in Treating Isocitrate Dehydrogenase (IDH)1/2-Mutant Grade I-IV Gliomas

Excerpt:
...- Subjects must have IDH1 or IDH2 mutation associated with neomorphic activity of the encoded proteins....
Trial ID:
Evidence Level:
Sensitive: D – Preclinical
Title:

Exploiting inherent DNA damage repair defects in IDH1/2 mutated gliomas with the CNS penetrant PARP inhibitor, pamiparib

Excerpt:
We also demonstrated significant, mutant IDH1 selective pamiparib sensitivity in vitro (IC50 0.67 vs. 141 uM)....Pamiparib is a promising, CNS penetrant PARP inhibitor that may selectively target IDH1/2 mutated gliomas, based on intrinsic HR defects associated with these tumors.